CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Margolin, Sara ^a   Eiberg, Hans ^b   Lindblom, Annika ^c   Bisgaard, Marie Luise ^b  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; DNA; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENETIC SCREENING; GENETIC VARIABILITY; HEREDITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PREVALENCE; SWEDEN; AGE DISTRIBUTION; BREAST TUMOR; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION;

ADULT; AGE DISTRIBUTION; AGE OF ONSET; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; PREVALENCE; PROTEIN-SERINE-THREONINE KINASES; SWEDEN;

EID: 34848862151     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-163     Document Type: Article

References (31)

1. Easton DF How many more breast cancer predisposition genes are there? Breast Cancer Res 1999, 1:14-17. 138504 11250676 10.1186/bcr6
2. Antoniou AC Pharoah PD McMullan G Day NE Stratton MR Peto J Ponder BJ Easton DF A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes Br J Cancer 2002, 86:76-83. 10.1038/ sj.bjc.6600008 11857015
3. Pharoah PD Antoniou A Bobrow M Zimmern RL Easton DF Ponder BA Polygenic susceptibility to breast cancer and implications for prevention Nat Genet 2002, 31:33-36. 10.1038/ng853 11984562
4. Dunning AM Healey CS Pharoah PD Teare MD Ponder BA Easton DF A systematic review of genetic polymorphisms and breast cancer risk Cancer Epidemiol Biomarkers Prev 1999, 8:843-854. 10548311
5. Antoniou AC Easton DF Polygenic inheritance of breast cancer: Implications for design of association studies Genet Epidemiol 2003, 25:190-202. 10.1002/gepi.10261 14557987
6. Bartek J Lukas J Chk1 and Chk2 kinases in checkpoint control and cancer Cancer Cell 2003, 3:421-429. 10.1016/S1535-6108(03)00110-7 12781359
7. Vahteristo P Bartkova J Eerola H Syrjakoski K Ojala S Kilpivaara O Tamminen A Kononen J Aittomaki K Heikkila P Holli K Blomqvist C Bartek J Kallioniemi OP Nevanlinna H A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer Am J Hum Genet 2002, 71:432-438. 379177 12094328 10.1086/341943
8. Meijers-Heijboer H van den Ouweland A Klijn J Wasielewski M de Snoo A Oldenburg R Hollestelle A Houben M Crepin E van Veghel-Plandsoen M Elstrodt F van Duijn C Bartels C Meijers C Schutte M McGuffog L Thompson D Easton D Sodha N Seal S Barfoot R Mangion J Chang-Claude J Eccles D Eeles R Evans DG Houlston R Murday V Narod S Peretz T Peto J Phelan C Zhang HX Szabo C Devilee P Goldgar D Futreal PA Nathanson KL Weber B Rahman N Stratton MR Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations Nat Genet 2002, 31:55-59. 10.1038/ng879 11967536
9. Oldenburg RA Kroeze-Jansema K Kraan J Morreau H Klijn JG Hoogerbrugge N Ligtenberg MJ van Asperen CJ Vasen HF Meijers C Meijers-Heijboer H de Bock TH Cornelisse CJ Devilee P The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families Cancer Res 2003, 63:8153-8157. 14678969
10. CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies Am J Hum Genet 2004, 74:1175-1182. 1182081 15122511 10.1086/421251
11. Lindblom A A molecular study on familial breast cancer Departments of Clinical Genetics and Oncology, Karolinska Hospital Stockholm, Karolinska Institute 1993
12. Zelada-Hedman M Wasteson Arver B Claro A Chen J Werelius B Kok H Sandelin K Hakansson S Andersen TI Borg A Borresen Dale AL Lindblom A A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region Cancer Res 1997, 57:2474-2477. 9192828
13. Chen J Hedman MZ Arver BW Sigurdsson S Eyfjord JE Lindblom A BRCA2 germline mutations in Swedish breast cancer families Eur J Hum Genet 1998, 6:134-139. 10.1038/sj.ejhg.5200167 9781057
14. Margolin S Werelius B Fornander T Lindblom A BRCA1 mutations in a population-based study of breast cancer in Stockholm County Genet Test 2004, 8:127-132. 15345109
15. Mateus Pereira LH Sigurdson AJ Doody MM Pineda MA Alexander BH Greene MH Struewing JP CHEK2:1100delC and female breast cancer in the United States Int J Cancer 2004, 112:541-543. 10.1002/ijc.20439 15382084
16. Meijers-Heijboer H Wijnen J Vasen H Wasielewski M Wagner A Hollestelle A Elstrodt F van den Bos R de Snoo A Fat GT Brekelmans C Jagmohan S Franken P Verkuijlen P van den Ouweland A Chapman P Tops C Moslein G Burn J Lynch H Klijn J Fodde R Schutte M The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype Am J Hum Genet 2003, 72:1308-1314. 1180284 12690581 10.1086/ 375121
17. Offit K Pierce H Kirchhoff T Kolachana P Rapaport B Gregersen P Johnson S Yossepowitch O Huang H Satagopan J Robson M Scheuer L Nafa K Ellis N Frequency of CHEK2* 1100delC in New York breast cancer cases and controls BMC Med Genet 2003, 4:1. 149355 12529183 10.1186/1471-2350-4-1
18. Jekimovs CR Chen X Arnold J Gatei M Richard DJ Spurdle AB Khanna KK Chenevix-Trench G Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: Functional analysis in heterozygous individuals Br J Cancer 2005, 92:784-790. 10.1038/ sj.bjc.6602381 15700044
19. Kleibl Z Novotny J Bezdickova D Malik R Kleiblova P Foretova L Petruzelka L Ilencikova D Cinek P Pohlreich P The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic Breast Cancer Res Treat 2005, 90:165-167. 10.1007/ s10549-004-4023-8 15803363
20. Osorio A Rodriguez-Lopez R Diez O de la Hoya M Ignacio Martinez J Vega A Esteban-Cardenosa E Alonso C Caldes T Benitez J The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population Int J Cancer 2004, 108:54-56. 10.1002/ijc.11414 14618615
21. Wagenius M Borg A Johansson L Giwercman A Bratt O CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden Scand J Urol Nephrol 2006, 40:23-25. 10.1080/ 00365590500368518 16452051
22. Isinger A Bhat M Borg A Nilbert M CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum BMC Cancer 2006, 6:64. 1421428 16539695 10.1186/1471-2407-6-64
23. Einarsdottir K Humphreys K Bonnard C Palmgren J Iles MM Sjolander A Li Y Chia KS Liu ET Hall P Liu J Wedren S Linkage disequilibrium mapping of CHEK2: Common variation and breast cancer risk PLoS Med 2006, 3:e168. 1457009 16671833 10.1371/journal.pmed.0030168
24. de Bock GH Schutte M Krol-Warmerdam EM Seynaeve C Blom J Brekelmans CT Meijers-Heijboer H van Asperen CJ Cornelisse CJ Devilee P Tollenaar RA Klijn JG Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2* 1100delC variant J Med Genet 2004, 41:731-735. 10.1136/jmg.2004.019737 15466005
25. Rasid MU Jakubowska A Justenhoven C Harth V Pesch B Baisch C Pierl CB Bruning T Ko Y Benner A Wichmann HE Brauch H Hamann U German populations with infrequent CHEK2* 1100delC and minor associations with early-onset and familial breast cancer Eur J Cancer 2005, 41:2896-2903. 10.1016/j.ejca.2005.04.049 16239104
26. Weischer M Bojesen SE Tybjaerg-Hansen A Axelsson CK Nordestgaard BG Increased risk of breast cancer associated with CHEK2* 1100delC J Clin Oncol 2007, 25:57-63. 10.1200/JCO.2005.05.5160 16880452
27. de Jong MM Nolte IM Te Meerman GJ van der Graaf WT Oosterom E Bruinenberg M Steege G Oosterwijk JC van der Hout AH Boezen HM Schaapveld M Kleibeuker JH de Vries EG No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors Eur J Cancer 2005, 41:1819-1823. 10.1016/ j.ejca.2005.04.035 16043347
28. Kilpivaara O Bartkova J Eerola H Syrjakoski K Vahteristo P Lukas J Blomqvist C Holli K Heikkila P Sauter G Kallioniemi OP Bartek J Nevanlinna H Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients Int J Cancer 2005, 113:575-580. 10.1002/ijc.20638 15472904
29. Bell DW Varley JM Szydlo TE Kang DH Wahrer DC Shannon KE Lubratovich M Verselis SJ Isselbacher KJ Fraumeni JF Birch JM Li FP Garber JE Haber DA Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome Science 1999, 286:2528-2531. 10.1126/science.286.5449.2528 10617473
30. Dufault MR Betz B Wappenschmidt B Hofmann W Bandick K Golla A Pietschmann A Nestle-Kramling C Rhiem K Huttner C von Lindern C Dall P Kiechle M Untch M Jonat W Meindl A Scherneck S Niederacher D Schmutzler RK Arnold N Limited relevance of the CHEK2 gene in hereditary breast cancer Int J Cancer 2004, 110:320-325. 10.1002/ijc.20073 15095295
31. Sodha N Houlston RS Bullock S Yuille MA Chu C Turner G Eeles RA Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome Hum Mutat 2002, 20:460-462. 10.1002/humu.10136 12442270